Harvard Bioscience Stock Price To Earnings To Growth
| HBIO Stock | USD 0.61 0.02 3.58% |
Harvard Bioscience fundamentals help investors to digest information that contributes to Harvard Bioscience's financial success or failures. It also enables traders to predict the movement of Harvard Stock. The fundamental analysis module provides a way to measure Harvard Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harvard Bioscience stock.
Harvard | Price To Earnings To Growth |
Harvard Bioscience Company Price To Earnings To Growth Analysis
Harvard Bioscience's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Harvard Bioscience Price To Earnings To Growth | 2.89 X |
Most of Harvard Bioscience's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harvard Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Harvard Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Harvard Bioscience is extremely important. It helps to project a fair market value of Harvard Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Harvard Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Harvard Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Harvard Bioscience's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Harvard Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Harvard Bioscience has a Price To Earnings To Growth of 2.89 times. This is 307.04% higher than that of the Life Sciences Tools & Services sector and notably lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 40.9% higher than that of the company.
Harvard Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harvard Bioscience's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harvard Bioscience could also be used in its relative valuation, which is a method of valuing Harvard Bioscience by comparing valuation metrics of similar companies.Harvard Bioscience is currently under evaluation in price to earnings to growth category among its peers.
Harvard Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0223 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 66.78 M | ||||
| Shares Outstanding | 44.07 M | ||||
| Shares Owned By Insiders | 7.05 % | ||||
| Shares Owned By Institutions | 82.23 % | ||||
| Number Of Shares Shorted | 906.62 K | ||||
| Price To Earning | (25.00) X | ||||
| Price To Book | 0.42 X | ||||
| Price To Sales | 0.28 X | ||||
| Revenue | 94.14 M | ||||
| Gross Profit | 54.81 M | ||||
| EBITDA | (1.3 M) | ||||
| Net Income | (12.4 M) | ||||
| Cash And Equivalents | 4.26 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 44.49 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 2.42 X | ||||
| Book Value Per Share | 1.44 X | ||||
| Cash Flow From Operations | 1.44 M | ||||
| Short Ratio | 3.29 X | ||||
| Earnings Per Share | (0.28) X | ||||
| Price To Earnings To Growth | 2.89 X | ||||
| Target Price | 3.75 | ||||
| Number Of Employees | 330 | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 26.4 M | ||||
| Total Asset | 126.64 M | ||||
| Retained Earnings | (158.01 M) | ||||
| Working Capital | (9.84 M) | ||||
| Current Asset | 50.55 M | ||||
| Current Liabilities | 19.32 M | ||||
| Net Asset | 126.64 M |
About Harvard Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harvard Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harvard Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harvard Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock: Check out Harvard Bioscience Piotroski F Score and Harvard Bioscience Altman Z Score analysis. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.